Dimitrova A, Todorova M, Bianov K, Halachev N, Dineva S, Elenkova A
Department of Cardiology, Medical University, Sofia, Bulgaria.
Folia Med (Plovdiv). 1998;40(3B Suppl 3):43-5.
Losartan is the first drug of a new class antihypertensive drags--Angiotensin II receptors antagonists. According to the data in the literature the drug shows a very good efficiency and tolerability. Fifteen patients at the average age of 48.9 are the object of this study. Our study establishes considerable lowering of the systolic BP with 15.9% and of the diastolic BP with 20.3%. No considerable effects on the hematopoiesis, the carbohydrate and the lipid metabolism, and the renal function were observed during treatment with Cozaar.
氯沙坦是新型抗高血压药物——血管紧张素II受体拮抗剂中的首个药物。根据文献数据，该药物显示出非常好的疗效和耐受性。本研究的对象是15名平均年龄为48.9岁的患者。我们的研究表明，收缩压显著降低了15.9%，舒张压显著降低了20.3%。在用科素亚治疗期间，未观察到对造血、碳水化合物和脂质代谢以及肾功能有显著影响。
